U.K. pharmaceutical company AstraZeneca on Thursday lost its appeal of a European court ruling that said it used anticompetitive tactics to prevent less-expensive copies of its popular heartburn pill Losec from entering the market, the European Union's top court said.
AstraZeneca loses appeal over market abuse charges
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.